Rongbo Lin, MD, on Gastric Cancer: Results From the FNF-004 Trial
2019 Gastrointestinal Cancers SymposiumRongbo Lin, MD, of Fujian Cancer Hospital, discusses phase II study findings on FOLFOX alone vs paclitaxel plus FOLFOX vs intraperitoneal paclitaxel plus FOLFOX as a first-line treatment in advanced gastric cancer (Abstract 6).
Related Videos
Andrew X. Zhu, MD, PhD, on Liver Cancer: Outcomes in the REFLECT Study on Lenvatinib
Andrew X. Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses an analysis of survival and objective response in patients with hepatocellular carcinom...
Heinz-Josef Lenz, MD, on BRAF V600E–Mutated Biliary Tract Cancer: Results From the ROAR Basket Trial
Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the efficacy and safety of dabrafenib and trametinib in patients ...
David H. Ilson, MD, PhD, on Gastric Cancer: Results From the TAGS Study on Third-Line Trifluridine/Tipiracil
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy and safety of third-line trifluridine/tipiracil in patients with metast...
Jeffrey A. Meyerhardt, MD, MPH, on Colon Cancer: Results From the ACTS-CC 02 Trial on Adjuvant Chemotherapy
Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses phase III study findings on S-1/oxaliplatin vs uracil and tegafur/leucovorin as adjuvant chemothera...
Andrew X. Zhu, MD, PhD, on Pancreatic Cancer: Results From the Prep-02/JSAP-05 Trial
Andrew X. Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses phase II/III study findings on neoadjuvant chemotherapy with gemcitabine and S-1 vs upf...
